Take Advantage of Vaxart’s Sharp Pullback, Says Analyst
The recent news of an adverse reaction suffered by a participant in AstraZeneca’s Covid-19 vaccine candidate’s clinical trial demonstrated that getting an approved vaccine to market is no straight forward matter. What the unfortunate event also shows, is that the race to be first across the finish line with a viable solution is far from over.
The field is still open, then, for vaccine specialist Vaxart (Click here to view the original article.
